Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Natashya_Fatale who wrote (369)	1/8/2005 8:52:22 PM
From: zeta1961	Respond to of 946

Thanks Dave for taking care.. Zeta

To: Natashya_Fatale who wrote (369)	1/9/2005 10:09:28 AM
From: quidditch	Read Replies (1) \| Respond to of 946

ok, need help in deciphering the Da Vinci Code here (in addition to zeta's reply): <<The Phase I dose escalation in lung cancer in San Antonio has everybody in oncology glued to their seats. At the present rate, it looks like much larger doses of paclitaxel/taxol can be run in on the 1st cycle than ever before, with much less toxicity.>> I'm confused by the bold faced text: The best answer is that: (a) with xyotax's lower tox profile in second or third line therapy to refractory cases, higher doses of first line paclitaxel/taxol can be administered in first line therapy; or (b) paclitaxel in this context refers to xyotax's polyglutamate polymer linked form of paclitaxel; or (c) it was a typo; or (d) none of the above. I suppose, given Natashya (David's) enthusiasm, "(b)" would be the best answer and the answer that would most please erik and the poper. quid (What goes through a player's mind when he delivers a forearm blow to the QB's head on what should be the defensive game saving last play of the game. It leaves a lot more than Drew Brees shaking his head.)